J 2011

History of treatment and long-term outcome in children with acute lymphoblastic leukemia in the Czech Republic

STARÝ, J., V. MIHÁL, P. SMÍŠEK, B. BLAŽEK, Y. JABALI et. al.

Basic information

Original name

History of treatment and long-term outcome in children with acute lymphoblastic leukemia in the Czech Republic

Authors

STARÝ, J. (203 Czech Republic, guarantor), V. MIHÁL (203 Czech Republic), P. SMÍŠEK (203 Czech Republic), B. BLAŽEK (203 Czech Republic), Y. JABALI (203 Czech Republic), Hana HRSTKOVÁ (203 Czech Republic, belonging to the institution), J. HAK (203 Czech Republic), D. PROCHÁZKOVÁ (203 Czech Republic), Z. ČERNÁ (203 Czech Republic), Jaroslav ŠTĚRBA (203 Czech Republic, belonging to the institution), J. TRKA (203 Czech Republic), O. HRUŠÁK (203 Czech Republic), J. ZUNA (203 Czech Republic), E. MEJSTŘÍKOVÁ (203 Czech Republic), I. JANOTOVÁ (203 Czech Republic), P. SEDLÁČEK (203 Czech Republic), H. PTOSZKOVÁ (203 Czech Republic), D. POSPÍŠILOVÁ (203 Czech Republic), K. TOUŠOVSKÁ (203 Czech Republic), P. TIMR (203 Czech Republic), V. VÁVRA (203 Czech Republic), K. ZDRÁHALOVÁ (203 Czech Republic), L. ŠRÁMKOVÁ (203 Czech Republic), Z. ZEMANOVÁ (203 Czech Republic), M. JAROŠOVÁ (203 Czech Republic), P. GAJDOŠ (203 Czech Republic) and O. HRODEK (203 Czech Republic)

Edition

memo - Magazine of European Medical Oncology, Springer, 2011, 1865-5041

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30201 Cardiac and Cardiovascular systems

Country of publisher

Austria

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

RIV identification code

RIV/00216224:14110/11:00059282

Organization unit

Faculty of Medicine

UT WoS

000219600900014

Keywords in English

Acute lymphoblastic leukaemia; children; treatment; diagnostics

Tags

International impact, Reviewed
Změněno: 4/10/2012 10:16, Mgr. Michal Petr

Abstract

V originále

Treatment of childhood acute lymphoblastic leukemia (ALL) was unifi ed in the year 1986 in the Czech Republic using BFM protocols. Patients and methods: Children were treated in 10 and later on in 8 centers localized at the pediatric departments of the biggest hospitals. More than 1.000 children and adolescents up to the age of 18 years were treated between 1986 and 2002 on three consecutive studies ALL-BFM 83, ALL-BFM 90 and ALL-BFM 95. Results: Event-free survival and overall survival improved gradually from 58/62% on ALL-BFM 83 through 70.5/76.6% on ALL-BFM 90 until 72.1/80.2% on ALL-BFM 95. At the same time the incidence of toxic deaths was decreasing and the success in the achievement of complete remission was increasing. Diagnostics in the Czech Republic improved remarkably in the 1990 with gradual introduction of centralized fl ow cytometry and molecular genetic analysis in one reference laboratory (CLIP = Childhood Leukemia Investigation Prague), which since then has become an internationally respected research center. Conclusions: Building up a network of closely collaborating leukemia centers covering the whole country, together with the establishment of reference and research laboratories has paved the way for the implementation of the Czech Pediatric Hematology Working Group (CPH) into the international studies Interfant 99, EsPhALL and for the active role in ALL IC-BFM 2002, the I-BFM-SG international randomized trial for treatment of children and adolescents with non-B ALL starting in 2002.